STOCK TITAN

NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

ADAR1 Capital Management, LLC and its sole manager Daniel Schneeberger report beneficial ownership of common stock of NextCure, Inc. ADAR1-managed private funds and separately managed accounts hold 722,419 shares of NextCure common stock, and these shares may be deemed indirectly beneficially owned by both ADAR1 and Schneeberger.

This position represents 15.8% of NextCure’s common stock, based on 4,577,359 shares outstanding as of July 31, 2026, as stated in the company’s Form 10-Q for the quarter ended June 30, 2026. Both reporting persons have shared voting and dispositive power over the 722,419 shares and no sole voting or dispositive power.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 722,419 shares Common stock of NextCure, Inc. reported by ADAR1 Capital Management and Daniel Schneeberger
Ownership percentage 15.8% Percent of NextCure common stock class beneficially owned by the reporting persons
Shares outstanding 4,577,359 shares NextCure common stock outstanding as of July 31, 2026, per Form 10-Q
Shared voting power 722,419 shares Shares of NextCure over which the reporting persons have shared voting power
Shared dispositive power 722,419 shares Shares of NextCure over which the reporting persons have shared dispositive power
beneficially owned financial
"Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 722,419.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 722,419.00"
control person financial
"Mr. Schneeberger is filing this as a control person in respect of shares beneficially owned"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviser financial
"ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E)."
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

How many NextCure (NXTC) shares does ADAR1 Capital Management report owning?

ADAR1 Capital Management reports beneficial ownership of 722,419 shares of NextCure common stock. These shares are held by private investment funds and separately managed accounts managed by ADAR1 and are subject to shared voting and dispositive power.

What percentage of NextCure (NXTC) does ADAR1 Capital Management and Daniel Schneeberger own?

ADAR1 Capital Management and Daniel Schneeberger report beneficial ownership of 15.8% of NextCure’s common stock. This percentage is based on 4,577,359 shares outstanding as of July 31, 2026, as disclosed in the company’s Form 10-Q.

Who are the reporting persons in this Schedule 13G for NextCure (NXTC)?

The reporting persons are ADAR1 Capital Management, LLC, a Texas limited liability company, and Daniel Schneeberger, a citizen of Switzerland and ADAR1’s sole manager. Both may be deemed to beneficially own the same 722,419 NextCure shares.

What kind of voting power does ADAR1 Capital Management have over NextCure (NXTC) shares?

ADAR1 Capital Management reports 0 shares with sole voting power and 722,419 shares with shared voting power. It also reports shared dispositive power over 722,419 shares and no sole dispositive power over any NextCure shares.

On what share count is the 15.8% ownership of NextCure (NXTC) based?

The reported 15.8% ownership is based on 4,577,359 shares of NextCure common stock outstanding as of July 31, 2026. This outstanding share figure comes from NextCure’s Form 10-Q for the quarter ended June 30, 2026.

In what capacity is Daniel Schneeberger reporting ownership of NextCure (NXTC) shares?

Daniel Schneeberger reports that the 722,419 shares may be deemed indirectly beneficially owned by him as the sole manager of ADAR1 Capital Management, LLC. He files in his individual capacity as a control person of ADAR1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





65343E207

(CUSIP Number)
07/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 722,419 shares of common stock, $0.001 par value per share ("Common Stock"), of NextCure, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 4,577,359 shares of Common Stock outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 722,419 shares of common stock, $0.001 par value per share ("Common Stock"), of NextCure, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC and separately managed accounts of ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 4,577,359 shares of Common Stock outstanding as of July 31, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2026
Exhibit Information

Exhibit A: Joint Filing Agreement